This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Dave Garman, PhD
Chief Technology Officer at NoNO, Inc.


Dr. Garman joined NoNO Inc in 2010 after 12 years in biotechnology business development to expand the company’s capabilities in preclinical development, clinical development and manufacturing. Dr. Garman has over 30 years of experience in laboratory science and has spent the past 18 years in biotechnology, holding various positions encompassing finance, quality assurance, manufacturing, intellectual property and business development. The last 13 years of this ectensive backround have been focused on the development of neurotherapeutics. Dr. Garman received his PhD in Developmental Biology from Stanford University.

Agenda Sessions

  • Chairman’s Remarks: Cell Penetrating Peptides for Targeting Intracellular Proteins or Protein Interactions